LifeMD (LFMD) director Calum MacRae granted 35,000 restricted shares in equity award

Rhea-AI Filing Summary

LifeMD, Inc. director Calum Archibald MacRae reported a grant of 35,000 shares of common stock as an equity award. The restricted shares were acquired at $0.00 per share and are scheduled to vest on June 1, 2027. Following this award, MacRae directly holds 73,865 shares of LifeMD common stock.

Insider Trade Summary

Net Buyer: 35,000 shares

Net Buy 1 txn

Insider MACRAE CALUM ARCHIBALD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	35,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 73,865 shares (Direct)

Footnotes (1)

1. F1. The grant of restricted shares vests on June 1, 2027.

Key Figures

Restricted shares granted: 35,000 shares Grant price per share: $0.00 per share Shares held after transaction: 73,865 shares +1 more

4 metrics

Restricted shares granted 35,000 shares Equity award to director on August 11, 2026

Grant price per share $0.00 per share Price for restricted share grant to director

Shares held after transaction 73,865 shares Director’s direct LifeMD common stock holdings post-award

Vesting date June 1, 2027 Scheduled vesting date for the 35,000 restricted shares

Key Terms

restricted shares, grant/award acquisition, vesting

3 terms

restricted shares financial

"The grant of restricted shares vests on June 1, 2027."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

grant/award acquisition financial

"transaction_action: grant/award acquisition for the equity award."

vesting financial

"The grant of restricted shares vests on June 1, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What did LifeMD (LFMD) director Calum Archibald MacRae report in this Form 4?

Calum Archibald MacRae reported a grant of 35,000 restricted shares of LifeMD common stock. These were awarded at $0.00 per share as an equity grant and increase his direct holdings to 73,865 shares.

When do the newly granted restricted shares to the LifeMD (LFMD) director vest?

The 35,000 restricted shares granted to director Calum Archibald MacRae vest on June 1, 2027. Until that vesting date, the shares are subject to the applicable vesting conditions described for this equity award.

How many LifeMD (LFMD) shares does Calum Archibald MacRae own after this transaction?

After the reported equity grant, Calum Archibald MacRae directly holds 73,865 shares of LifeMD common stock. This total reflects the addition of 35,000 restricted shares from the August 11, 2026 award.

Was the LifeMD (LFMD) Form 4 transaction a market purchase or sale?

The Form 4 reports a grant/award acquisition of 35,000 restricted shares at $0.00 per share. It was not a market purchase or sale but an equity compensation award to the director.

Is the LifeMD (LFMD) Form 4 transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the equity award is coded as a grant/award acquisition. There is no indication in the data that this grant was executed under a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 05:49 PM Accepted by SEC EDGAR 08/13/2026 - 05:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACRAE CALUM ARCHIBALD

(Last) (First) (Middle)

C/O LIFEMD, INC.

236 FIFTH AVENUE, 4TH FLOOR

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		A		35,000(1)	A	$0	73,865	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant of restricted shares vests on June 1, 2027.

	/s/ Calum Archibald MacRae	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)